The DEA (Drug Enforcement Administration, the agency that controls which drugs are legal and how strictly) won't downgrade psilocybin or MDMA from their current 'most dangerous, no accepted use' category in 2026. That can only happen after the FDA (the US drug safety regulator) formally approves one of these substances as a medicine — and no approval is close enough to trigger that process this year. This matters because reclassification is what would make these drugs legally accessible beyond tightly controlled research settings.
Scheduling decisions for Schedule I substances follow FDA approval with a clean label and abuse-potential data, not public momentum. No such approval is positioned to trigger DEA action within the calendar year.